Plain-English translation of NCT04449991 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
Lupus nephritis is a serious kidney condition that affects more than one-third of people with lupus. This study is testing whether taking a second kidney biopsy (a small tissue sample) at 12 months after starting treatment can help doctors better understand how well the treatment is working and whether you need additional medication.
Current blood and urine tests don't always show the true state of the kidney tissue. Some patients appear to be doing well based on standard tests, but their kidney tissue still shows signs of disease that could benefit from stronger treatment. This study aims to see if a repeat biopsy helps doctors catch these hidden problems early and prevent long-term kidney damage.
You likely qualify if…
You likely don't qualify if…
You will start standard lupus kidney disease treatment and be monitored with regular blood and urine tests. If randomly assigned to the biopsy group, you will return at 12 months for a second kidney biopsy to see how your kidney tissue has responded to treatment. Either way, you'll continue regular clinic visits and blood work to track your progress over time. The study will follow you for at least one year, with some patients followed longer to see long-term kidney outcomes.
AI-generated summary from trial data · Jun 11, 2026 · Not medical advice
Sweden